Markowitz D, Hesdorffer C, Ward M, Goff S, Bank A
Department of Genetics, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
Ann N Y Acad Sci. 1990;612:407-14. doi: 10.1111/j.1749-6632.1990.tb24328.x.
One of the requirements for the use of retroviral vectors in human gene therapy is a packaging cell line which is incapable of producing replication-competent virus and which produces high titers of replication-deficient vector virus. Wild-type virus may be produced through recombinational events between the helper virus and a retroviral vector. We have constructed an ecotropic packaging cell line, GP + E-86, and an amphotropic packaging cell line, GP + envAm12, in which the viral gag and pol genes are on one plasmid and the viral env gene is on another plasmid. Both plasmids contain deletions of the packaging sequence and the 3' LTR. The fragmented helper virus genomes, when introduced into 3T3 cells, produce titers of retrovirus which are comparable to the titers produced from packaging cells containing the helper virus genome on a single plasmid. We have found no evidence for the generation of wild-type retrovirus using the GP + E-86 and GP + envAm12 packaging lines, either alone or in combination with the N2 retroviral vector. We also show that these packaging cell lines can be used to transfer the neoR gene of the N2 vector into mouse hematopoietic cells, followed by successful (48-52%), long-term (up to 200 days) transplantation into irradiated recipients. These results indicate that these packaging lines are safe and efficient for use in experiments designed for murine (using GP + E-86) and human (using GP + envAm12) gene therapy.
在人类基因治疗中使用逆转录病毒载体的要求之一是要有一个包装细胞系,该细胞系不能产生具有复制能力的病毒,但能产生高滴度的复制缺陷型载体病毒。野生型病毒可能通过辅助病毒与逆转录病毒载体之间的重组事件产生。我们构建了一个嗜亲性包装细胞系GP + E - 86和一个兼嗜性包装细胞系GP + envAm12,其中病毒gag和pol基因位于一个质粒上,病毒env基因位于另一个质粒上。两个质粒都缺失了包装序列和3' LTR。当将片段化的辅助病毒基因组导入3T3细胞时,产生的逆转录病毒滴度与从含有单个质粒上的辅助病毒基因组的包装细胞产生的滴度相当。我们没有发现使用GP + E - 86和GP + envAm12包装细胞系单独或与N2逆转录病毒载体联合使用时产生野生型逆转录病毒的证据。我们还表明,这些包装细胞系可用于将N2载体的neoR基因转移到小鼠造血细胞中,随后成功(48 - 52%)、长期(长达200天)移植到受辐照的受体中。这些结果表明,这些包装细胞系在用于小鼠(使用GP + E - 86)和人类(使用GP + envAm12)基因治疗的实验中是安全有效的。